文献速递白血病造血干细胞移植与细胞治疗

帕纳替尼联合贝林妥欧单抗治疗费城染色体阳性急性淋巴细胞白血病:美国单中心单臂2期试验

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2022-11-16

在美国MD安德森癌症中心开展的單中心、单臂2期试验中,60例费城染色体阳性急性淋巴细胞白血病或慢性髓系白血病淋系急变期患者接受帕纳替尼联合贝林妥欧单抗的无化疗方案。新诊断患者完全分子学缓解率为87%(33/38),复发/难治患者总缓解率为92%(12/13),慢性髓系白血病淋系急变期患者总缓解率为83%(5/6)。

要点

  • 新诊断费城染色体阳性急性淋巴细胞白血病患者完全分子学缓解率达87%(33/38)。
  • 复发/难治患者总缓解率为92%(12/13),完全分子学缓解率为79%(11/13)。
  • 常见3-4级不良事件为感染(37%)、淀粉酶或脂肪酶升高(8%)等,无治疗相关死亡。

核心结论

  • 帕纳替尼联合贝林妥欧单抗的无化疗方案在新诊断及复发/难治费城染色体阳性急性淋巴细胞白血病患者中产生高比例完全分子学缓解。
  • 新诊断费城染色体阳性急性淋巴细胞白血病患者或可免于化疗相关毒性和首次缓解后异基因造血干细胞移植的需求。

研究设计与样本

  • 美国德克萨斯大学MD安德森癌症中心单中心、单臂2期试验,纳入年龄≥18岁的新诊断或复发/难治费城染色体阳性急性淋巴细胞白血病或慢性髓系白血病淋系急变期患者。
  • 2018年2月6日至2022年5月6日期间,评估72例患者中60例(83%)入组并接受帕纳替尼联合贝林妥欧单抗治疗。
  • 治疗方案:帕纳替尼30 mg口服联合贝林妥欧单抗28 μg持续静脉输注24小时(每周期28天),最多5个42天周期,随后帕纳替尼单药治疗;并接受12次鞘内化疗作为中枢神经系统预防。
  • 主要终点:新诊断患者的完全分子学缓解(PCR检测BCR-ABL1转录本灵敏度0.01%不可测)及复发/难治或慢性髓系白血病淋系急变期患者的总缓解率。
  • 试验注册号NCT03263572,2022年3月23日修订增加入组30例使样本量增至90例,试验正在进行中。

主要发现

  • 入组60例患者中,新诊断费城染色体阳性急性淋巴细胞白血病40例(67%),复发/难治费城染色体阳性急性淋巴细胞白血病14例(23%),慢性髓系白血病淋系急变期6例(10%)。
  • 32例(53%)为男性,28例(47%)为女性;51例(85%)为白人或有西班牙裔血统;中位年龄51岁(IQR 36-68)。
  • 全队列中位随访时间16个月(IQR 11-24)。
  • 新诊断费城染色体阳性急性淋巴细胞白血病可评估患者38例中33例(87%)达完全分子学缓解;复发/难治可评估患者13例中12例(92%)达总缓解,11例(79%)达完全分子学缓解;慢性髓系白血病淋系急变期6例中5例(83%)达总缓解,2例(33%)达完全分子学缓解。
  • 发生率>5%的最常见3-4级不良事件:感染22例(37%)、淀粉酶或脂肪酶升高5例(8%)、丙氨酸氨基转移酶或天冬氨酸氨基转移酶升高4例(7%)、疼痛4例(7%)、高血压4例(7%);1例(2%)因震颤停用贝林妥欧单抗;3例(5%)分别因脑血管缺血、门静脉血栓和冠状动脉狭窄停用帕纳替尼;未观察到治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ponatinib and blinatumomab are effective therapies in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their combination might be a promising treatment option. In this study, we aimed to evaluate this chemotherapy-free strategy. METHODS: We did a single-centre, single-arm, phase 2 study at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, in patients aged 18 years or older with newly diagnosed or relapsed or refractory Ph-positive acute lymphoblastic leukaemia or chronic myeloid leukaemia in lymphoid blast phase. Patients with an ECOG performance status of 2 or less who had a total bilirubin concentration two-times the upper limit of normal (ULN) or less (≤2·4 mg/dL), alanine aminotransferase and aspartate aminotransferase concentration no more than three-times the ULN, and serum lipase and amylase concentrations no more than three-times the ULN were eligible for inclusion. Ponatinib 30 mg orally and continuous intravenous blinatumomab 28 μg over 24 h (for 28 days each cycle) were given in combination for up to five 42-day cycles, followed by ponatinib monotherapy. Patients received 12 doses of intrathecal chemotherapy as CNS prophylaxis. The primary endpoints were complete molecular response (defined as absence of a detectable BCR-ABL1 transcript by PCR at a sensitivity of 0·01%) in patients with newly diagnosed disease and overall response in patients with relapsed or refractory disease or chronic myeloid leukaemia in lymphoid blast phase. All assessments were done according to the intention-to-treat principle. The trial completed its original target accrual and was amended on March 23, 2022, to enrol an additional 30 patients, thus increasing the sample size to 90 patients. The trial is registered with ClinicalTrials.gov, NCT03263572, and it is ongoing. FINDINGS: Between Feb 6, 2018, to May 6, 2022, 60 (83%) of 72 patients assessed were enrolled and received ponatinib and blinatumomab (40 [67%] patients had newly diagnosed Ph-positive acute lymphoblastic leukaemia, 14 [23%] had relapsed or refractory Ph-positive acute lymphoblastic leukaemia, and six [10%] had chronic myeloid leukaemia in lymphoid blast phase). 32 (53%) patients were men and 28 (47%) were women; 51 (85%) patients were White or Hispanic; and the median age of participants was 51 years (IQR 36-68). The median duration of follow-up for the entire cohort was 16 months (IQR 11-24). Of patients with newly diagnosed Ph-positive acute lymphoblastic leukaemia, 33 (87%) of 38 evaluable patients had a complete molecular response. 12 (92%) of 13 evaluable patients with relapsed or refractory Ph-positive acute lymphoblastic leukaemia had an overall response. 11 (79%) had a complete molecular response. Five (83%) of six patients with chronic myeloid leukaemia in lymphoid blast phase had an overall response. Two (33%) had a complete molecular response. The most common grade 3-4 adverse events that occurred in more than 5% of patients were infection (22 [37%] patients), increased amylase or lipase concentration (five [8%] patients), increased alanine aminotransferase or aspartate aminotransferase concentration (four [7%] patients), pain (four [7%] patients), and hypertension (four [7%] patients). One (2%) patient discontinued blinatumomab due to tremor. Three (5%) patients discontinued ponatinib secondary to cerebrovascular ischaemia, portal vein thrombosis, and coronary artery stenosis in one patient each. No treatment-related deaths were observed. INTERPRETATION: The chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response in patients with newly diagnosed and relapsed or refractory Ph-positive acute lymphoblastic leukaemia. Patients with newly diagnosed Ph-positive acute lymphoblastic leukaemia could be spared the toxicities associated with chemotherapy and the need for allogeneic haematopoietic stem-cell transplantation in first response. FUNDING: Takeda Oncology and Amgen.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022. PMID: 36402146. doi:10.1016/S2352-3026(22)00319-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。